Oxybate Drug Asset Due Diligence Report 2026

This Oxybate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Oxybate can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Oxybate (query alias: Oxybate)
Modality / target	Small molecule drug; Not disclosed; Not disclosed
Highest global status	NDA/BLA
Originator	Tris Pharma, Inc.
Active developers	Tris Pharma, Inc.

The MCP disease footprint includes Cataplexy, Excessive Daytime Sleepiness, Idiopathic Hypersomnia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2500110811	Phase 4	Pending	48	The difference between the mean arterial pressure immediately before endotracheal intubation and the baseline mean arterial pressure before induction of anesthesia was measured in all patients
NCT06950281	Phase 2	Not yet recruiting	52	Change in average weekly frequency of nocturnal cluster headache attacks (verum vs placebo)
NCT07596342	Phase 2	Not yet recruiting	24	Deep slow-wave sleep

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Long-term Safety and Efficacy of Extended-release Once-nightly Sodium Oxybate for Narcolepsy in Patients not Currently Taking an Oxybate

Phase 3; n=50; evaluation: Positive. Reported fields: Cataplexy episodes(change from baseline) = -8.3 Point ( -12.1 to -4.6)

Sodium oxybate versus midazolam for end-of-life continuous deep sedation: a randomised controlled trial

Phase 4; n=22; evaluation: Positive. Reported fields: Treatment Success = 0.0 % ( 0 - 28.5); Treatment Success = 100.0 % ( 71.5 - 100)

213 Successful Transition From Twice-Nightly Oxybates to Once-Nightly Sodium Oxybate: A Post Hoc Analysis From RESTORE

Phase 3; n=130; evaluation: Positive. Reported fields: TEAE(discontinuation) = 5.4 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Oxybate addresses Cataplexy, Excessive Daytime Sleepiness, Idiopathic Hypersomnia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-11-26	Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid	Phase 1	US$2,250.0M stated total
2025-10-22	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market	Approved	US$2,370.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO